Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -42

Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock

Earnings report AI-generated analysis

πŸ“‰ Boston Scientific shares have returned +10.2% over the past month, outperforming the S&P 500 composite which fell -2%.

πŸ“Š The company reported quarterly revenues of $5.14 billion, a +1.4% increase year-over-year, beating consensus estimates by 0.68%.

πŸ’° Reported earnings per share were $0.73, missing the Zacks Consensus Estimate of $0.78 by approximately 6.7%.

πŸ“‰ Analysts have revised the current quarter's earnings estimate down by -2.5% and the fiscal year estimate down by -2.6% over the last month.

πŸ† Boston Scientific received a Zacks Rank #5 (Strong Sell) due to negative trends in earnings estimate revisions.

πŸ’΅ The company holds a Zacks Value Style Score of C, indicating it is currently trading at par with its industry peers.

Bullish Signals
  • Boston Scientific reported quarterly revenues of $5.14 billion, representing a +1.4% year-over-year increase.
  • The company beat the Zacks Consensus Revenue Estimate for the current quarter by +0.68%.
Risk Factors
  • Analysts have revised the consensus earnings estimate for the current quarter down by -2.5% from the year-ago period.
  • The Zacks Consensus Estimate for the current fiscal year has decreased by -2.6% over the last 30 days.
  • Boston Scientific missed the quarterly EPS consensus estimate of $0.78, reporting actual earnings of $0.73 per share.
  • The company has been assigned a Zacks Rank #5 (Strong Sell), suggesting it may underperform the broader market in the near term.
Full Analysis
Boston Scientific Corporation (BSX) has recently been a trending stock, with shares gaining +10.2% over the past month compared to the S&P 500's decline. The company operates within the Zacks Medical Products industry, which has seen significant gains during this period. However, fundamental analysis suggests caution due to recent downward revisions in earnings projections. Analysts have lowered their consensus earnings estimates for the current quarter by -2.5% and for the fiscal year by -2.6%. Consequently, Boston Scientific has received a Zacks Rank #5 (Strong Sell), indicating a high probability of near-term underperformance relative to the broader market. This rating is driven primarily by negative trends in earnings estimate revisions over the last 30 days. Financial performance data shows mixed results with reported revenues of $5.14 billion representing a +1.4% year-over-year increase, while consensus estimates for the current quarter suggest a -1.9% decline. The company beat revenue expectations by 0.68% but missed earnings expectations exactly, reporting EPS of $0.73 versus an estimate of $0.78. Valuation metrics place the stock at par with peers, receiving a Zacks Value Style Score of C.